The primary efficacy endpoint — DCB success at 12 months, defined as a composite of primary patency without clinically driven bailout stenting — was reported in 78.8% in the Chocolate Touch ...

The DCB (Lutonix 035 Drug-Coated Balloon PTA Catheter) was previously approved for treatment of lesions in the superficial femoral and popliteal arteries, according to a press release issued by ...

The five-year results for the ILLUMENATE Pivotal study also show no statistically significant difference among patients treated with the Stellarex DCB (21.2%) compared to those treated with PTA ...

Given that the Chocolate Touch DCB was designed in part to lower the risk for intimal dissection, "I found it interesting that there were no dissections in both the treatment and the comparator ...

Meta-analysis of two major randomized controlled trials (RCTs) show no difference in mortality between patients treated with the Philips Stellarex drug-coated balloon (DCB) and those treated with ...